复方新诺明对急性淋巴细胞白血病患儿甲氨蝶呤药代动力学的影响。

Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia.

作者信息

Beach B J, Woods W G, Howell S B

出版信息

Am J Pediatr Hematol Oncol. 1981 Summer;3(2):115-9. doi: 10.1097/00043426-198100320-00001.

DOI:10.1097/00043426-198100320-00001

Abstract

The effect of co-trimoxazole on methotrexate (MTX) pharmacokinetics was studied in seven children with ALL in remission receiving weekly maintenance therapy. Each child received MTX alone during one course, and MTX with co-trimoxazole during the next. Co-trimoxazole did not cause any significant alteration in either intestinal absorption of MTX, the degree of MTX plasma protein binding, or the average concentration X time exposure to MTX. These results indicate that low doses of co-trimoxazole do not perturb the serum pharmacokinetics of MTX. However, interaction of these drugs at the cellular level still remains a distinct possibility.

摘要

在七名接受每周维持治疗且处于缓解期的急性淋巴细胞白血病（ALL）儿童中，研究了复方新诺明对甲氨蝶呤（MTX）药代动力学的影响。每个孩子在一个疗程中单独接受MTX，在下一个疗程中接受MTX与复方新诺明联合治疗。复方新诺明对MTX的肠道吸收、MTX血浆蛋白结合程度或MTX的平均浓度×时间暴露量均未引起任何显著改变。这些结果表明，低剂量的复方新诺明不会干扰MTX的血清药代动力学。然而，这些药物在细胞水平上的相互作用仍极有可能存在。